Steerage Capital Inc. lowered its stake in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 17.4% in the course of the 2nd quarter, HoldingsChannel.com studies. The fund owned 8,205 shares of the biopharmaceutical firm’s inventory after promoting 1,734 shares in the course of the quarter. Steerage Capital Inc.’s holdings in Bristol-Myers Squibb had been value $341,000 on the finish of the latest quarter.
A number of different giant traders have additionally added to or decreased their stakes in BMY. Nice Diamond Companions LLC raised its place in Bristol-Myers Squibb by 9.2% within the 4th quarter. Nice Diamond Companions LLC now owns 4,372 shares of the biopharmaceutical firm’s inventory value $224,000 after shopping for a further 367 shares over the last quarter. World Belongings Advisory LLC bought a brand new stake in Bristol-Myers Squibb within the first quarter value roughly $5,161,000. Principal Securities Inc. purchased a brand new stake in Bristol-Myers Squibb within the 4th quarter value roughly $1,139,000. Lincoln Nationwide Corp lifted its holdings in shares of Bristol-Myers Squibb by 7.7% in the course of the 1st quarter. Lincoln Nationwide Corp now owns 42,894 shares of the biopharmaceutical firm’s inventory valued at $2,326,000 after shopping for a further 3,052 shares in the course of the interval. Lastly, Chapin Davis Inc. boosted its place in Bristol-Myers Squibb by 22.6% within the first quarter. Chapin Davis Inc. now owns 22,544 shares of the biopharmaceutical firm’s inventory value $1,223,000 after buying a further 4,159 shares over the last quarter. Institutional traders personal 76.41% of the corporate’s inventory.
Analyst Upgrades and Downgrades
A number of equities analysts have just lately weighed in on BMY shares. Jefferies Monetary Group elevated their worth goal on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the inventory a “maintain” score in a analysis word on Wednesday, August twenty eighth. StockNews.com upgraded shares of Bristol-Myers Squibb from a “purchase” score to a “strong-buy” score in a analysis word on Monday, July twenty ninth. Deutsche Financial institution Aktiengesellschaft decreased their worth goal on Bristol-Myers Squibb from $53.00 to $45.00 and set a “maintain” score for the corporate in a analysis word on Tuesday, July twenty third. Barclays lifted their goal worth on Bristol-Myers Squibb from $41.00 to $42.00 and gave the corporate an “underweight” score in a analysis report on Thursday, August twenty second. Lastly, TD Cowen upped their worth goal on Bristol-Myers Squibb from $45.00 to $53.00 and gave the inventory a “maintain” score in a analysis report on Monday, August twelfth. Two funding analysts have rated the inventory with a promote score, 13 have issued a maintain score, two have assigned a purchase score and one has issued a powerful purchase score to the inventory. In response to information from MarketBeat, Bristol-Myers Squibb has a consensus score of “Maintain” and a consensus worth goal of $54.67.
View Our Newest Inventory Report on Bristol-Myers Squibb
Bristol-Myers Squibb Buying and selling Up 0.5 %
Shares of BMY opened at $49.95 on Tuesday. Bristol-Myers Squibb has a 1 yr low of $39.35 and a 1 yr excessive of $63.03. The corporate has a 50 day easy shifting common of $45.32 and a two-hundred day easy shifting common of $46.56. The corporate has a debt-to-equity ratio of two.86, a present ratio of 1.16 and a fast ratio of 1.02. The agency has a market cap of $101.25 billion, a P/E ratio of -16.11, a price-to-earnings-growth ratio of 12.92 and a beta of 0.44.
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) final posted its earnings outcomes on Friday, July twenty sixth. The biopharmaceutical firm reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a unfavourable internet margin of 14.06% and a optimistic return on fairness of 12.51%. The corporate had income of $12.20 billion in the course of the quarter, in comparison with analysts’ expectations of $11.54 billion. Throughout the identical interval final yr, the corporate posted $1.75 earnings per share. Bristol-Myers Squibb’s quarterly income was up 8.7% on a year-over-year foundation. On common, equities analysts count on that Bristol-Myers Squibb will publish 0.77 earnings per share for the present fiscal yr.
Bristol-Myers Squibb Proclaims Dividend
The corporate additionally just lately declared a quarterly dividend, which was paid on Thursday, August 1st. Buyers of file on Friday, July fifth had been paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized foundation and a yield of 4.80%. The ex-dividend date of this dividend was Friday, July fifth. Bristol-Myers Squibb’s payout ratio is presently -77.42%.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Firm discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical merchandise worldwide. It affords merchandise for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience ailments. The corporate’s merchandise embody Eliquis for discount in threat of stroke/systemic embolism in non-valvular atrial fibrillation, and for the therapy of DVT/PE; Opdivo for numerous anti-cancer indications, together with bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, abdomen and esophageal most cancers; Pomalyst/Imnovid for a number of myeloma; Orencia for energetic rheumatoid arthritis and psoriatic arthritis; and Sprycel for the therapy of Philadelphia chromosome-positive power myeloid leukemia.
Featured Tales
Need to see what different hedge funds are holding BMY? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Free Report).
Obtain Information & Rankings for Bristol-Myers Squibb Every day – Enter your e mail tackle under to obtain a concise every day abstract of the most recent information and analysts’ rankings for Bristol-Myers Squibb and associated firms with MarketBeat.com’s FREE every day e mail e-newsletter.
